Equities researchers at Deutsche Bank set a $107.00 price target on shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) stock in a research report issued on Wednesday, Stock Ratings Network.com reports. Deutsche Bank’s target price points to a potential upside of 16.82% from the company’s current price.
A number of other firms have also recently commented on AEGR. Analysts at Canaccord Genuity raised their price target on shares of Aegerion Pharmaceuticals from $90.00 to $110.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Needham & Company reiterated a “buy” rating on shares of Aegerion Pharmaceuticals in a research note to investors on Tuesday. They now have a $100.00 price target on the stock. Finally, analysts at Needham & Company raised their price target on shares of Aegerion Pharmaceuticals from $50.00 to $100.00 in a research note to investors on Monday, July 22nd. They now have a “buy” rating on the stock.
Eight equities research analysts have rated the stock with a buy rating, Aegerion Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $81.54.
Shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) traded up 3.62% during mid-day trading on Wednesday, hitting $94.905. Aegerion Pharmaceuticals has a one year low of $12.87 and a one year high of $97.46. The stock’s 50-day moving average is currently $71.79. The company’s market cap is $2.735 billion.
Aegerion Pharmaceuticals (NASDAQ:AEGR) last released its earnings data on Tuesday, July 30th. The company reported ($0.66) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.62) by $0.04. The company had revenue of $6.50 million for the quarter, compared to the consensus estimate of $4.27 million. On average, analysts predict that Aegerion Pharmaceuticals will post $-2.16 earnings per share for the current fiscal year.
Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.